Comparison of Early-onset Efficacy of Anti-calcitonin Gene-related Peptide Monoclonal Antibodies for Patients with Migraine in Real-world Clinical Practice: Study Protocol for an Exploratory Clinical Trial

Three anti-calcitonin gene-related peptide monoclonal antibodies (CGRP-mAbs) are available in Japan: galcanezumab, fremanezumab, and erenumab. Early-onset efficacy has been demonstrated for each CGRP-mAb in comparison with placebo, but differences among the drugs are unclear. Only galcanezumab requi...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Takafumi TANEI, Satoshi MAESAWA, Yusuke NISHIMURA, Tomotaka ISHIZAKI, Yoshitaka NAGASHIMA, Miki HASHIDA, Shun YAMAMOTO, Masahiko ANDO, Yachiyo KUWATSUKA, Atsushi HASHIZUME, Toshihiko WAKABAYASHI, Ryuta SAITO
Format:	Artigo
Jezik:	Inglês
Izdano:	The Japan Neurosurgical Society 2025-02-01
Serija:	Neurologia Medico-Chirurgica
Teme:	early-onset efficacy anti-calcitonin gene-related peptide monoclonal antibody cgrp migraine discontinuation
Online dostop:	https://www.jstage.jst.go.jp/article/nmc/65/2/65_2024-0201/_pdf/-char/en
Oznake:	Označite Brez oznak, prvi označite!